Sökning: "Antirheumatic agents"

Visar resultat 1 - 5 av 6 avhandlingar innehållade orden Antirheumatic agents.

1. 1. Disease activity, function and costs in early rheumatoid arthritis

   Författare :Eva Hallert; Thomas Skogh; Jan Persson; Ronald van Vollenhoven; Linköpings universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Antirheumatic agents; Rheumatoid arthritis; Cost of illness; Health care costs; Joints physiopathology; Sex factors; Rheumatology; Reumatologi;

   Sammanfattning : Rheumatoid arthritis (RA) is a major cause of progressive joint damage and disability, and is associated with decline in quality of life, reduced ability to work and increased health care utilisation. The economic consequences of the disease are substantial for the individuals and their families and for the society as a whole. LÄS MER

3. 2. Health economics and its measures in rheumatoid arthritis

   Författare :Johan Karlsson; Reumatologi och molekylär skelettbiologi; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cost-utility analysis; Cost-of-illness; Quality of life; EuroQol 5-Dimensions; Antirheumatic agents; TNF inhibition; Outcome assessment; Disease activity; Disability; Health economics; Rheumatoid arthritis;

   Sammanfattning : Objectives: To study: (I) the impact on cost-utility analyses of applying different national EuroQol 5-Dimensions (EQ-5D) preference sets; (II and III) whether, in methotrexate-refractory, early rheumatoid arthritis (RA), the addition of infliximab results in superior health-related quality of life (HRQoL) and may be considered cost-effective, as compared to adding sulfasalazine and hydroxychloroquine; (IV) how costs relate to disability (measured by the health-assessment questionnaire, HAQ), disease activity (28-joint disease activity score, DAS28) and HRQoL (EQ-5D) in RA. Methods: In the observational SSATG register, one-year quality-adjusted life-year (QALY) accumulation of two interventions was compared according to the UK, US, or Danish EQ-5D preference sets. LÄS MER

4. 3. Endothelial cell interactions with neutrophils : studies of adhesion and effects of lipoxygenase metabolites and antirheumatic drugs

   Författare :Mikael Heimbürger; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :adhesion; auranofin; endothelium; gold sodium thiomalate; leukotrienes; lipoxins; neutrophils; PPAR; prednisolone;

   Sammanfattning : Inflammation is a process of vital importance in the defence and elimination of microorganisms as well as in the repair of the damaged tissue. However, inadequate or excessive inflammation leads to inflammatory diseases such as rheumatoid arthritis. LÄS MER

5. 4. Biological therapy in rheumatoid arthritis : epidemiological studies

   Författare :Katerina Chatzidionysiou; Karolinska Institutet; Karolinska Institutet; []
   Nyckelord :;

   Sammanfattning : The landscape of RA treatment has unquestionably changed dramatically during the last decade. A deeper understanding of the pathophysiological and immunological mechanisms in RA, earlier and more aggressive treatment, and the development and introduction to daily clinical practice of a new class of antirheumatic drugs, the so-called biologic therapies, has contributed to this ‘revolution’. LÄS MER

7. 5. Treatment of arthritis with tumour necrosis factor antagonists. Clinical, immunological and biochemical aspects

   Författare :Meliha C Kapetanovic; Reumatologi och molekylär skelettbiologi; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Skelett; muskelsystem; reumatologi; Skeleton; muscle system; rheumatology locomotion; ANA; infusion reaction; influenza vaccination; pneumococcal vaccination; COMP; TNF antagonists; spondylarthropathies; arthritis; rheumatoid arthritis;

   Sammanfattning : Abstract The treatment of arthritis has undergone a dramatic change since biological agents targeting specific mediators of the disease process have been introduced. Tumour necrosis factor (TNF) antagonists have been shown to reduce signs and symptoms of disease and to retard the development of tissue damage in the majority of patients. LÄS MER